Rethinking cancer vaccines through the tumour immunopeptidome
Researchers are advancing cancer vaccine development by utilizing immunopeptidome analysis to identify specific tumor-derived antigens. This approach aims to create more effective, personalized immunotherapies by targeting the unique mutational profiles of individual patients.
Why it matters
Personalized cancer vaccines represent a major shift in oncology, potentially offering more durable and effective treatments compared to traditional therapies.
Direct identification of specific tumour-derived HLA-bound peptide targets is enabling the development of personalised immunotherapy strategies
Initially promising research in cancer vaccination has failed time and again to translate into an approved cancer treatment. Immunopeptidome analysis enables peptides to be effectively ‘washed’ directly from the tumour cell surface to provide specific information about the antigens presented by a tumour to the immune system. The latest tools enable precise selection of key antigens for personalised vaccine development , and three main strategies are being explored for the clinical development and application of peptide-based cancer vaccines: ‘off-the-shelf’ vaccines based on common human leukocyte antigen (HLA) allotypes or highly frequent tumour antigens; pre-manufactured immunopeptidome-defined ‘warehouse’ antigens that may be used to assemble multi-peptide, patient-tailored products; and personalised vaccines produced in real time based on a patient’s tumour mutational profile and tumour-specific peptides.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in